Advertisement

Tumor Biology

, Volume 33, Issue 6, pp 2289–2298 | Cite as

PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group

  • Watcharin Loilome
  • Sasithorn Yooyuen
  • Nisana Namwat
  • Paiboon Sithithaworn
  • Anucha Puapairoj
  • Junko Kano
  • Masayuki Noguchi
  • Masanao Miwa
  • Puangrat Yongvanit
Research Article

Abstract

Cholangiocarcinoma (CCA) associated with Opisthorchis viverrini (Ov) chronic infection is the most frequent primary liver cancer in Thailand, and current approaches to early diagnosis and curative treatments are largely disappointing. We hypothesize a role for protein kinase A (PKA) in Ov-induced CCA. First, we studied the PKA isozyme switching in the liver from the hamster CCA model using quantitative (q) PCR, in situ hybridization, and immunohistochemical and western blot analysis. Second, the presence of extracellular PKA (ECPKA) in CCA cell lines and their conditioned media was demonstrated by western blot and PKA activity assay. Third, we determined the association between PRKAR1A expression and serum ECPKA autoantibody in patients with CCA by ELISA. We demonstrated that an increased PRKAR1A expression is restricted to the biliary cells starting from week 1, with remarkable up-regulation when CCA has completely developed by week 24. The switching of the PKA regulatory subunit isoforms from PRKAR2B/PKAII to PRKAR1A/PKAI is significantly associated with cholangiocyte proliferation. Further, we observed that human CCA cell lines express PRKAR1A but not PRKAR2B and excrete ECPKA. Finally, ECPKA autoantibodies are detected in serum of patients with CCA, adenocarcinoma, and Ov infection with periductal fibrosis, but not from Ov-infected subjects without periductal fibrosis lesion and healthy controls. We conclude that PKA isozyme switching and the PRKAR1A/PKAI pathway might contribute to the induction of cholangiocyte transformation and proliferation in Ov-induced CCA. Overexpression of PRKAR1A leads to secretion of ECPKA which is associated with serum autoantibody that may constitute a biomarker for human CCA genesis.

Keywords

Cholangiocarcinoma PKA isozyme switching ECPKA autoantibody Periductal fibrosis 

Notes

Acknowledgments

This work was supported by Khon Kaen University Research Fund (Grant No. 46-03-1-01-04) to PY, Thailand Research Fund (TRF) (Grant No. MRG4980174) to WL, Research Strengthening Grant from BIOTEC-NSTDA, Thailand, and the Higher Education Research Promotion and National Research University Project of Thailand, Office of the Higher Education Commission, through the Health Cluster (SHeP-GMS), Khon Kaen University. We thank Professor Carlo Selmi for his editorial assistance.

Conflict of interest

None

References

  1. 1.
    Loilome W, Yongvanit P, Wongkham C, Tepsiri N, Sripa B, Sithithaworn P, et al. Altered gene expression in Opisthorchis viverrini-associated cholangiocarcinoma in hamster model. Mol Carcinog. 2006;45:279–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Loilome W, Juntana S, Namwat N, Bhudhisawasdi V, Puapairoj A, Sripa B, et al. PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer. 2011;129:34–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Cho-Chung YS, Pepe S, Clair T, Budillon A, Nesterova M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol. 1995;21:33–61.PubMedCrossRefGoogle Scholar
  4. 4.
    Gonzalez GA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell. 1989;59:675–80.PubMedCrossRefGoogle Scholar
  5. 5.
    Krebs EG. Protein kinases. Curr Top Cell Regul. 1972;5:99–133.PubMedGoogle Scholar
  6. 6.
    Cho-Chung YS. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res. 1990;50:7093–100.PubMedGoogle Scholar
  7. 7.
    Tortora G, Clair T, Cho-Chung YS. An antisense oligodeoxynucleotide targeted against the type ii beta regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. Proc Natl Acad Sci USA. 1990;87:705–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Tortora G, Ciardiello F. Protein kinase a as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci. 2002;968:139–47.PubMedCrossRefGoogle Scholar
  9. 9.
    Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer. 1994;69:738–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Miller WR, Watson DM, Jack W, Chetty U, Elton RA. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat. 1993;26:89–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Cho YS, Lee YN, Cho-Chung YS. Biochemical characterization of extracellular cAMP-dependent protein kinase as a tumor marker. Biochem Biophys Res Commun. 2000;278:679–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Cho YS, Park YG, Lee YN, Kim MK, Bates S, Tan L, et al. Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression. Proc Natl Acad Sci USA. 2000;97:835–40.PubMedCrossRefGoogle Scholar
  13. 13.
    Cvijic ME, Kita T, Shih W, DiPaola RS, Chin KV. Extracellular catalytic subunit activity of the cAMP-dependent protein kinase in prostate cancer. Clin Cancer Res. 2000;6:2309–17.PubMedGoogle Scholar
  14. 14.
    Kita T, Goydos J, Reitman E, Ravatn R, Lin Y, Shih WC, et al. Extracellular cAMP-dependent protein kinase (ECPKA) in melanoma. Cancer Lett. 2004;208:187–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Nesterova MV, Johnson N, Cheadle C, Bates SE, Mani S, Stratakis CA, et al. Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res. 2006;66:8971–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Sripa B, Kaewkes S. Localisation of parasite antigens and inflammatory responses in experimental opisthorchiasis. Int J Parasitol. 2000;30:735–40.PubMedCrossRefGoogle Scholar
  17. 17.
    Sripa B, Mairiang E, Thinkhamrop B, Laha T, Kaewkes S, Sithithaworn P, et al. Advanced periductal fibrosis from infection with the carcinogenic human liver fluke Opisthorchis viverrini correlates with elevated levels of interleukin-6. Hepatology. 2009;50:1273–81.PubMedCrossRefGoogle Scholar
  18. 18.
    Pinlaor S, Yongvanit P, Hiraku Y, Ma N, Semba R, Oikawa S, et al. 8-Nitroguanine formation in the liver of hamsters infected with Opisthorchis viverrini. Biochem Biophys Res Commun. 2003;309:567–71.PubMedCrossRefGoogle Scholar
  19. 19.
    Hsu SM, Raine L. Protein A, avidin, and biotin in immunohistochemistry. J Histochem Cytochem. 1981;29:1349–53.PubMedCrossRefGoogle Scholar
  20. 20.
    Skarpen E, Thoresen GH, Tasken K, Samuelsen JT, Jahnsen T, Schwarze PE, et al. Localization of cAMP-dependent signal transducers in early rat liver carcinogenesis. Histochem Cell Biol. 1998;109:203–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Pinlaor S, Ma N, Hiraku Y, Yongvanit P, Semba R, Oikawa S, et al. Repeated infection with Opisthorchis viverrini induces accumulation of 8-nitroguanine and 8-oxo-7,8-dihydro-2′-deoxyguanine in the bile duct of hamsters via inducible nitric oxide synthase. Carcinogenesis. 2004;25:1535–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Batheja N, Suriawinata A, Saxena R, Ionescu G, Schwartz M, Thung SN. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod Pathol. 2000;13:1265–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Kohno Y, Patel V, Kim Y, Tsuji T, Chin BR, Sun M, et al. Apoptosis, proliferation and p12(doc-1) profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol. 2002;38:274–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Yue H, Jiang HY. Expression of cell cycle regulator p57kip2, cycline protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study. World J Gastroenterol. 2005;11:5057–60.PubMedGoogle Scholar
  25. 25.
    Fujii H, Yang Y, Tang R, Kunitomo K, Itakura J, Mogaki M, et al. Epithelial cell proliferation activity of the biliary ductal system with congenital biliary malformations. J Hepatobiliary Pancreat Surg. 1999;6:294–302.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee CS. Differences in cell proliferation and prognostic significance of proliferating cell nuclear antigen and ki-67 antigen immunoreactivity in in situ and invasive carcinomas of the extrahepatic biliary tract. Cancer. 1996;78:1881–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Nishida T, Nakao K, Hamaji M, Nakahara MA, Tsujimoto M. Prognostic significance of proliferative cell nuclear antigen in carcinoma of the extrahepatic bile duct. World J Surg. 1997;21:634–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN. Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. J Natl Cancer Inst. 1993;85:971–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Jonckheere N, Perrais M, Mariette C, Batra SK, Aubert JP, Pigny P, et al. A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. Oncogene. 2004;23:5729–38.PubMedCrossRefGoogle Scholar
  30. 30.
    Schiller M, Verrecchia F, Mauviel A. Cyclic adenosine 3′,5′-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism. Oncogene. 2003;22:8881–90.PubMedCrossRefGoogle Scholar
  31. 31.
    Prakobwong S, Pinlaor S, Yongvanit P, Sithithaworn P, Pairojkul C, Hiraku Y. Time profiles of the expression of metalloproteinases, tissue inhibitors of metalloproteases, cytokines and collagen in hamsters infected with Opisthorchis viverrini with special reference to peribiliary fibrosis and liver injury. Int J Parasitol. 2009;39(7):825–35.PubMedCrossRefGoogle Scholar
  32. 32.
    Prakobwong S, Yongvanit P, Hiraku Y, Pairojkul C, Sithithaworn P, Pinlaor P, et al. Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. Int J Cancer. 2010;127:2576–87.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  • Watcharin Loilome
    • 1
  • Sasithorn Yooyuen
    • 1
  • Nisana Namwat
    • 1
  • Paiboon Sithithaworn
    • 2
  • Anucha Puapairoj
    • 3
  • Junko Kano
    • 4
  • Masayuki Noguchi
    • 4
  • Masanao Miwa
    • 5
  • Puangrat Yongvanit
    • 1
  1. 1.Department of Biochemistry and Liver Fluke and Cholangiocarcinoma Research Center, Faculty of MedicineKhon Kaen UniversityKhon KaenThailand
  2. 2.Department of Parasitology and Liver Fluke and Cholangiocarcinoma Research Center, Faculty of MedicineKhon Kaen UniversityKhon KaenThailand
  3. 3.Department of Pathology and Liver Fluke and Cholangiocarcinoma Research Center, Faculty of MedicineKhon Kaen UniversityKhon KaenThailand
  4. 4.Department of Pathology, Institute of Basic Medical SciencesUniversity of TsukubaTsukubaJapan
  5. 5.Faculty of BioscienceNagahama Institute of Bio-Science and TechnologyNagahamaJapan

Personalised recommendations